SILVER SPRING, Md., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its contractor, Inno Biologics Sdn. Bhd., is using the Clone-Pix™ technology for the isolation and selection of clones preparatory to obtaining the large numbers of cells for Nuvilex's future clinical trials in advanced, inoperable pancreatic cancer.
Clone-Pix™ is considered to be "state-of–the-art" technology in the cloning process. It is an instrument that allows for the automated isolation of high value clones of mammalian cells. Clone-Pix™ is now employed by more than 100 laboratories and entities throughout the world and is used by notable pharmaceutical and biotech companies such as Merck, GlaxoSmithKline, Wyeth and Genentech. By employing this technology, workflow throughout the cloning process is increased and this allows for more clones to be screened in less time than would be possible using conventional technologies.
Clone-Pix™ allows for the gentle "picking" of clones to ensure high viability of the selected clones. The "best clones" for Nuvilex's purposes will be isolated, tested and propagated to obtain the requisite numbers of cells for cellulose-based encapsulation that will ultimately form part of Nuvilex's treatment for advanced pancreatic cancer. The most desirable of the selected clones will be those that have elevated activity of the enzyme that converts the cancer prodrug ifosfamide into its cancer-killing form.
Nuvilex's Chief Scientific Officer, Dr. Robert F. Ryan commented, "Through the use of Clone-Pix™, Inno Biologics will be able to optimize the selection of the most desirable clones for Nuvilex to use in producing adequate numbers of cells for our future late-phase clinical trials as expeditiously as possible. The availability of the Clone-Pix™ technology at Inno Biologics was a significant factor in our choosing that company to conduct this very important phase of our preparations for those trials."
Nuvilex is a biotechnology company with the rights to a novel cellulose-based live-cell encapsulation technology, called Cell-in-a-Box™, that will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and diabetes are being built. The Company's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon the well-known chemical constituents of marijuana. Nuvilex is exploring ways in which the Cell-in-a-Box™ technology may play a role in these efforts.
This press release may contain forward-looking statements regarding Nuvilex and its future events and results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding Nuvilex's financial position, business strategy, plans and objectives of management for future operations and business conditions are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties. Important factors, many of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, the following: (i) general economic or business conditions; (ii) changes in legislation or regulatory requirements; (iii) conditions of the securities markets; (iv) Nuvilex's ability to raise capital; (v) changes in accounting principles, policies or guidelines; (vi) financial or political instability; and (vii) other economic, competitive, governmental, regulatory and technical factors affecting the plans, operations, products and services of Nuvilex.
Nuvilex has based these forward-looking statements on its current expectations and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond the control of Nuvilex. Nuvilex does not assume any obligations to update any of these forward-looking statements.
More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting Investor Relations.
CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 email@example.com